Joselito Cabacar, MD
Nephrology · Baltimore, MDNPI 1356362594
Payments from drug & device makers
Across 462 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$1K
- Mallinckrodt Hospital Products Inc.$918
- Akebia Therapeutics Inc$768
- Bayer$768
- Vifor Pharma, Inc.$685
- plus $5K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 72 | $1,593 |
| AstraZeneca(2 entities) | 58 | $1,392 |
| Mallinckrodt Hospital Products Inc. | 30 | $918 |
| Akebia Therapeutics Inc | 39 | $768 |
| Bayer | 35 | $768 |
| Vifor Pharma, Inc. | 35 | $685 |
| Boehringer Ingelheim | 20 | $508 |
| GSK | 20 | $464 |
| Fresenius USA Marketing, Inc. | 21 | $441 |
| Novartis | 18 | $420 |
| Otsuka America Pharmaceutical, Inc. | 18 | $395 |
| Mallinckrodt Enterprises LLC | 6 | $293 |
| Travere Therapeutics, Inc. | 26 | $243 |
| Calliditas Therapeutics US Inc. | 13 | $242 |
| Ardelyx, Inc. | 10 | $212 |
| Aurinia Pharma U.S., Inc. | 8 | $170 |
| Livanova USA, Inc. | 1 | $140 |
| Lilly USA, LLC | 5 | $130 |
| Corcept Therapeutics | 5 | $125 |
| Neurelis, Inc. | 1 | $124 |
| ANI Pharmaceuticals, Inc. | 4 | $113 |
| Bard Peripheral Vascular, Inc. | 1 | $96 |
| Alnylam Pharmaceuticals Inc. | 4 | $93 |
| Nxstage Medical, Inc. | 1 | $63 |
| Novo Nordisk | 3 | $58 |
| Scpharmaceuticals Inc. | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| AbbVie | 1 | $26 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Medtronic | 1 | $22 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
How this compares
$10,634 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Baltimore
- Christopher SperatiBaltimore$1.5M
- Michelle EstrellaBaltimore$1.2M
- Mohamed AttaBaltimore$1.1M
- Chirag ParikhBaltimore$1M
- Matthew WeirBaltimore$518K
- Duvuru GeethaBaltimore$409K
- Preeti ChandraBaltimore$287K
- Morgan GramsBaltimore$260K
- Mohamad HanounehBaltimore$174K
- Stephen SeligerBaltimore$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.